Skip to content
NYSE: IGC | Borse Berlin: IGS1.BE | Frankfurt: IGS1
IGC

IGC

India Globalization Capital Inc.

  • Home
  • Annual Meeting of Stockholders
  • Life Sciences
  • Infrastructure Business
  • Investors
    • Press Releases
    • SEC Filings
    • XBRL Files
    • Leadership
    • Governance
    • Letter to Our Stockholders

IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

September 8, 2021September 8, 2021 by Alejandro
Posted in News and Filings, Press Releases

Post navigation

← IGC FYE2022 Form 10-Q1
IGC FYE2021 DEF 14A – Proxy Statement →

Site Map

  • Home
  • Annual Meeting of Stockholders
  • Life Sciences
  • Infrastructure Business
  • Investors
    • Press Releases
    • SEC Filings
    • XBRL Files
    • Leadership
    • Governance
    • Letter to Our Stockholders

Contact

IGC
Potomac, MD, United States

info@igcinc.us
301-983-0998